Remarks/Arguments:

Claims 1 to 54 were pending and before the Examiner. Claims 6-8, 10, 12-15, 16 in part, 17-23, 25-31 and 33-54 have been withdrawn. Claims 1-3, 16, 24 and 32 have been amended. Claims 1-5, 9, 11, 16, 24 and 32, as amended, are now pending and before the Examiner. Support for the amendments can be found throughout the specification, for example on pages 15 and 17.

Priority

Applicants submit herewith copies of the English translations of the German Patent Applications 102 56 081, filed November 29, 2002, and 103 30 686, filed July 8, 2003, as well as the translator's Declarations. Furthermore, applicants note an English translation for US provisional application 60/487,902, filed July 17, 2003, as well as a Declaration of the translator was filed with the Patent Office on December 2, 2004. A copy of the submission is enclosed herewith. Applicants therefore maintain that priority is in order.

Objections

Claim 16 has been objected to as being depending on the nonelected claim 14. Claim 16 has been amended to depend on elected claim 11. Accordingly, applicants respectfully request that the Examiner reconsider and withdraw the objection.

Rejections

In the communication mailed March 8, 2006, claims 1-3, and 9-11 have been rejected under 35 U.S.C §112, second paragraph, as being allegedly indefinite because according to the office action it is unclear what phosphotransferase gene is being referred to. While applicants respectfully disagree, in response, applicants have amended the claims to reference a neomycin phosphotransferase gene that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2. Accordingly, applicants respectfully request that the Examiner reconsider and withdraw the rejection.

Claim 24 has been rejected under 35 U.S.C §112, second paragraph, as being allegedly indefinite because according to the office action it does not sufficiently distinguish between cells in vitro and in the body. While applicants respectfully disagree,

Application No. 10/724,301 Amendment Dated June 6, 2006 Reply to Office action of March 8, 2006

in response, applicants have amended claim 24 to recite "in vitro." Accordingly, applicants respectfully request that the Examiner reconsider and withdraw the rejection.

Claim 32 has been rejected under 35 U.S.C §112, second paragraph, as being allegedly indefinite because according to the office action the preamble does not state what enrichment is referred to. While applicants respectfully disagree, in response, applicants have amended claim 32 to recite "a method of enriching for mammalian cells that express a modified neomycin-phosphotransferase gene." Accordingly, applicants respectfully request that the Examiner reconsider and withdraw the rejection.

Claim 1-3, 9-11, 24 and 32 have been rejected under 35 U.S.C. §112, first paragraph, for allegedly failing to comply with the written description requirement. While the applicants respectfully disagree, applicants have amended the claims to refer to a neomycin phosphotransferase gene that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 with specified modifications. Accordingly, applicants respectfully request that the Examiner reconsider and withdraw the rejection.

Claim 1-3, 9-11, 24 and 32 have been rejected under 35 U.S.C. §112, first paragraph, for allegedly failing to enable all modified neomycin phosphtransferases. While the applicants respectfully disagree, applicants have amended the claims to refer to a neomycin phosphotransferase gene that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 with specified modifications. Applicants maintain that it is well within the skill of the art to make and use the claimed invention. Accordingly, applicants respectfully request that the Examiner reconsider and withdraw the rejection.

Application No. 10/724,301 Amendment Dated June 6, 2006 Reply to Office action of March 8, 2006

Applicants maintain that the remarks above render the Examiner's rejections moot as to all the pending claims. Applicants therefore submit that all the pending claims are allowable and respectfully solicit a Notice of Allowance for all of the pending claims. If the Examiner feels that a telephone interview would be helpful in advancing prosecution of this application, the Examiner is invited to contact the attorney below.

Respectfully submitted,

Paula K. Wittmayer

Attorney for Applicant(s)

Reg. No. 53,785

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368 Ridgefield, CT. 06877 Tel.: (203) 791-6692

Tel.: (203) 791-6692 Dated: June 6, 2006 I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail (#EV449712166US) in an envelope addressed to:

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Paula K.

Reg. No. 53,785

on June 6, 2006



Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 791-6692

Date: June 6, 2006

"EXPRESS MAIL" LABEL NO.: EV449712166US DEPOSIT DATE: June 6, 2006 DOCKET NO: 1/1411

I HEREBY CERTIFY THAT THE PAPERS OR FEES LISTED BELOW ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND ADDRESSED TO:

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Paula K. Wittmayer Reg. No. 53,785

Enclosures:

- 1. Express Mail Certificate (1 page)
- 2. Amendment (15 pages)
- 3. Figures (4 pages)
- 4. Copy of return postcard mailed on December 2, 2004; stamped by the USPTO on December 6, 2004 (1 page)
- 5. Copy of Submission of English Translation Serial No. 60/487,902 statement, dated December 2, 2004 (1 page)
- 6. Copy of Translator's Declaration of English Translation, submitted December 2, 2004 (1 page)
- 7. Copy of English Translation Serial No.60/487,902, submitted December 2, 2004 (99 pages including drawings)
- 8. Translator's Declaration of English Translation of German Patent Application 102 56 081 (1 page)
- 9. English Translation of German Patent Application 102 56 081
- 10. Translator's Declaration of English Translation of German Patent Application 103 30 686 (1 page)
- 11. English Translation of German Patent Application 103 30 686
- 12. Return Post Card

Application No. 10/724,301 Amendment Dated June 6, 2006 Reply to Office action of March 8, 2006

Amendments to the Drawings:

The attached sheets of drawings include changes to Fig. 5 and Fig. 6A. These sheets, which include Fig. 5 and Fig. 6A, replace the original sheets including Fig. 5 and Fig. 6A. In Fig. 5 and Fig. 6A, the description of the X-axis has been translated from German to English.

Attachments:

Replacement Sheets (2)

Annotated Sheets Showing Changes (2)

NPT-Asp227Gly, 400 µg G418 Translated from German to English NPT-Glu182Asp, 400 µg G418 □/spezif. Prod (pg/Zelle*Tag) ■ Titer (mg/L) Reply to Office action of March 8, 2006 Annotated Sheet Showing Changes Amdt. Dated June 6, 2006 Appl. No. 10/724,301 NPT-WT, 800 µg G418 NPT-WT, 400 µg G418 Figure 5 0.400 0.00 0.300 0.200 0.100 Titre and specific productivity

Figure 6A

Appl. No. 10/724,301 Amdt. Dated June 6, 2006 Reply to Office action of March 8, 2006 Annotated Sheet Showing Changes

